Updates of incretin‐related drugs for the treatment of type 2 diabetes
Main Authors: | Hirotaka Araki, Takeshi Matsumura, Noboru Furukawa, Eiichi Araki |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-02-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.13945 |
Similar Items
-
Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01) -
Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01) -
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01) -
Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review
by: Akira Mima, et al.
Published: (2023-09-01) -
The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
by: Soyeon Yoo, et al.
Published: (2021-06-01)